brucellosis is a human- and animal-borne epidemic caused by brucellosis, which is widely distributed around the world and has serious implications for human health and livestock development. Antibacterial treatment is a key component of brucellosis treatment and is described in more detail below. Principles of treatment
The treatment of antibacterial drugs for brucellosis is based on the principles of early, joint, adequate and adequate treatment. Early diagnosis and timely treatment can be effective in increasing cure rates and reducing the incidence of complications. Joint use of antibacterial drugs can create synergies to enhance antibacterial effects and prevent the production of resistant bacteria. Sufficient use of the drug ensures that the drug reaches an effective antibacterial or fungicide concentration in the body, while the treatment is intended to eliminate the disease completely and avoid a relapse.
II. Common antibacterial drugs
1. Dossi cycline: This is one of the first-line drugs commonly used to treat brucellosis. It is an antibiotic of tetracyclics, with broad-spectrum resistance and better inhibition for brucellosis. Dossi cyclic oral intake is good, with a general adult dose of 100 mg per dose twice a day. Common adverse effects include gastrointestinal discomfort, such as nausea, vomiting, abdominal pain, and, in some cases, photo-sensitivity, with care to avoid direct sunlight during medication.
Li Fuping: Also a first-line treatment, Li Fuping has a strong microbicide of brucellosis. It inhibits the bacteria RNA polymerase, thus hindering the bacteria ‘ transfer process. Adults use a common dose of 600 – 900 mg per day, once a day, with an empty stomach. The adverse effects of Lifuping are mainly hepatotoxicity, which can lead to elevated remission enzymes, gastrointestinal reactions, allergies, etc. The liver function needs to be closely monitored during the use of the drug.
3. Chainicillin: It is an antibiotic of caramino sugar, which has played an important role in the treatment of brucellosis and is currently one of the most common options for joint use. Cycin is antibacterial by inhibiting the synthesis of bacterial proteins. Adults received a daily dose of 1 g, with 1 – 2 muscle injections. The main adverse effects are ear toxicity and renal toxicity, which can lead to reduced hearing, ringing, kidney function impairment, etc., and therefore require close attention to changes in the patient ‘ s hearing and kidney function during use.
4. Quintacin: It is also an antibiotic of amino sugar, which can be used for the treatment of brucellosis. It has a wider antibacterial spectrum and some inhibition of brucellosis. Adults used 160 – 240 mg per day for 2 – 3 intravenous drips or muscle injections. Gyptacin is also subject to adverse effects such as ear and kidney toxicity, with caution in its use.
5. Left oxen fluoride: Antibacterial drugs such as quinone have also been used in the treatment of brucellosis in recent years. It acts as an antibacterial by inhibiting the activity of the bacterial DNA rotor enzymes and hindering the reproduction of bacterial DNA. The average adult dose was 200 – 300 mg per day, two times a day. Common adverse effects are gastrointestinal reaction, central nervous system response, etc., such as nausea, headache, etc.
III. Joint drug programme
1. The standard programme recommended by the World Health Organization (WHO) is Dossi Cyclogen Uliforpine, which is normally for six weeks. Such joint programmes can achieve better treatment outcomes in most patients, with two drugs performing antibacterial functions from different mechanisms and working together to suppress brucellosis.
2. In some cases where the condition is severe or there are complications, a programme of Dossi Cycin, Lifuping Union or Quintacin can be used. Cycin or cytocin can further enhance antibacterial effects, but because of its toxic effects, the indicators need to be monitored more carefully when used.
IV. Therapeutic process and efficacy evaluation
The treatment of brucellosis is usually long, usually 6-8 weeks or longer, depending on the patient’s condition, treatment response, etc. In the course of treatment, the patient is regularly assessed for clinical symptoms, such as heat, joint pain, lack of strength, and laboratory examinations, including haematology, serology, etc., to determine whether the disease has been completely eliminated. If repeated symptoms during treatment or laboratory tests still indicate the presence of bacteria, there may be a need to adjust treatment programmes and extend the course of treatment.
In short, antibacterial treatment for brucellosis is a systematic and cautious process. Accurate selection of appropriate antibacterial drugs and the use of joint, adequate and pediatric drugs in strict compliance with the principles of treatment, while closely monitoring the adverse reactions of patients and the effects of treatment, will be effective in improving the cure rate, improving the quality of life of patients and preventing the recurrence and spread of disease.
